ClinicaliQ Trial Snapshot
- Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes — Recruiting • Phase III • Diabetes / Metabolic • NCT07284901.
- What is being tested: Ribupatide (KAI-9531), a once-weekly subcutaneous injection, is being evaluated for its efficacy in reducing body weight and improving glycaemic control (HbA1c) compared to placebo in patients with obesity or overweight and concurrent diabetes.
- Patient eligibility overview: The trial recruits adults living with obesity or overweight who also have diabetes mellitus, representing a population with significant cardiometabolic risk requiring dual therapeutic benefit.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
Eligibility Snapshot
- Key Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus (T2DM). * Receiving stable therapy for T2DM for 3 months prior to Screening. This includes diet and/or exercise alone or in combination with any oral medication for T2DM treatment except for DPP-4 inhibitors. Participants can be treatment naïve if they have an HbA1c of 6.5% to 7.5%, inclusive. * BMI ≥27 kg/m^2. * History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months. Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.